Intellectually Impaired People

Intellectually Impaired People: The Ongoing Battle addresses challenges against the background of history, changing societal environments, and current intellectual approaches and attitudes toward persons with disabilities. The book discusses national and international conventions, societal attitudes, sheltered workshops, the right of intellectually impaired persons for self-responsibility and its limitations, and the place of mentally impaired persons in the public image. Additionally, the book attempts to capture the forces that drive the changes of our conceptual frameworks. The US Tuskegee study which withheld antibiotics from black men with syphilis was not ended by scientific criticism but by a courageous man, press reports, and a changed social perception. The non-hiding of handicapped children is not the result of government orders, there are many non-resolvable dilemmas and tension between supporting, understanding, and patronizing a complex situation with many potential future avenues. - Recognizes how contradictory feelings and attitudes toward impaired persons have a complex historical background - Sheds light on society and our institutions that deal with disabled people and the limitations of an isolated medical approach - Covers national and international conventions of mentally impaired persons

Dr. Klaus Rose is a medical doctor by training and profession. In the 1990s, after clinical training, he joined the pharmaceutical industry. In 1999 at Novartis in Switzerland, he came across clinical studies in children and was intrigued. His eldest daughter suffered from Sturge-Weber syndrome, which is serious and very rare. Dr. Rose became passionate about 'pediatric drug development” and what the European Medicines Agency (EMA) called 'Better Medicines for Children.” He became global head pediatrics at Novartis from 2001-2005 and moved to the same position 2005-2009 at Genentech/Roche. After one more year at a regulatory company, he became an independent consultant in 2011. He advises companies on EMA 'pediatric investigation plans” (PIPs), and Food and Drug Administration (FDA) pediatric requests or demands. He detected fundamental flaws in 'Pediatric Drug Development' and publishes about this (and more) in peer-reviewed journals and medical textbooks.